share_log

康宁杰瑞制药-B(09966.HK):于2024年ASCO年会呈列的JSKN003治疗晚期实体瘤的I/II期临床研究的最新研究成果

Corning Jerry Pharmaceutical-B (09966.HK): The latest findings of the JSKN003 Phase I/II clinical study on advanced solid tumors presented at the 2024 ASCO Annual Meeting

Gelonghui Finance ·  Jun 2 18:36

On June 3, Gelunhui announced that the results of JSKN003-102's Phase I/II clinical trial for the treatment of advanced solid tumors in patients have been presented during the poster exhibition of the 2024 ASCO Annual Meeting (abstract number: 3031; poster number: 176), and the company's website has also published this study result.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment